期刊文献+

经皮冠状动脉介入术后氯吡格雷抵抗的临床观察 被引量:3

下载PDF
导出
摘要 目的观察因急性冠脉综合征(ACS)行冠状动脉介入治疗(PCI)患者应用氯吡格雷后血小板聚集率的变化及氯吡格雷抵抗的发生情况。方法ACS患者37例,予氯吡格雷负荷量300mg,继予75mg/d维持,在服用氯吡格雷前,服药后2、4、6、24、48h以及服药后30d取血,测定ADP诱导的血小板聚集率,观察血小板聚集率变化并根据抑制程度判断氯吡格雷抵抗发生率。结果给药后2、4、6、24、48h及30d时。氯吡格雷抵抗的发生率分别为62%、46%、32%、38%、49%和43%,氯吡格雷抵抗者用药后血小板抑制率明显低于反应者,其中1例抵抗者出现亚急性支架内血栓形成。结论PCI治疗的部分患者中存在氯吡格雷抵抗。
出处 《柳州医学》 2010年第4期141-143,共3页
基金 广西区卫生厅自筹经费项目
  • 相关文献

参考文献7

  • 1Jaremo P,Lindahl TL,Fransson SG,et al.Individual variations of platelet inhibition after loading doses of clopidogrel[].Journal of Interactive Marketing.2002
  • 2Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity[].Circulation.2003
  • 3The GUSTO Investigators.An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction[].New England Journal of Medicine The.1993
  • 4Muller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement[].Thrombosis and Haemostasis.2003
  • 5Lau W C,Gurbel P A,Watkins P B,et al.Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance[].Circulation.2004
  • 6Soffer D,Moussa I,Harjai K J,et al.Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina[].Catheterization and Cardiovascular Interventions.2003
  • 7Matetzky S,Shenkman B,Guetta V,et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction[].Circulation.2004

同被引文献25

  • 1叶任高,陆再英.内科学.第6版.北京:人民卫生出版社,2008:948-991.
  • 2Xu F, Lv S, Chen Y, et al. Macrophage inflammatory protein - 1 and fibrinogen are synergistic predictive markers of prognosis of interme- diate coronary artery hsions [J]. Cardiology, 2012, 121 (1) : 12 - 19.
  • 3Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial re- vascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC) and the European Associa- tion for Cardio-Thoracic Surgery(EACTS) [ J]. Eur Heart J, 2010, 31 (20) :2501 -2555.
  • 4Aradi D, Kom6csi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary in- tervention: systematic review and meta-analysis [ J ]. Am Heart J, 2010,160(3) :543 -551.
  • 5Cuisset T, Cayla G, Silvain J. Clopidogrel resistance: what new? [J]. Arch Cardiovasc Dis, 2010, 103(6/7) :349 -353.
  • 6Thygesen K, Alpert JS, Jaffe AS, et al. Third Universal definition of myocardial infarction[J]. J Am Coll Cardiol, 2012, 33 (20) : 2551 - 2567.
  • 7Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions [ J ]. Circu- lation, 2007, 115(17) :2344 -2351.
  • 8Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting[ J]. Thromb Res, 2005, 115( 1/2 ) : 101 - 108.
  • 9Angiolillo D J, Femqandez-Ortiz A, Bemardo E, et al. Platclet aggre- gation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? [ J ]. J lnvasive Cardiol, 2004, 16 (4) : 169 - 174.
  • 10Tantry US, Jeong YH, Navarese EP, et al. Influence of genetic pol- ymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease[J]. Expert Rev Cardiovosc Ther, 2013, 11 (4):447-462.

引证文献3

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部